Related Experiment Videos

Double-blind randomized trial of nicotinamide on early-onset diabetes

C M Lewis1, D M Canafax, J M Sprafka

  • 1Department of Medicine, School of Medicine, College of Pharmacy, University of Minnesota, Minneapolis 55455.

Diabetes Care
|January 1, 1992
PubMed
Abstract

Insights

Nicotinamide did not induce remission in early-onset insulin-dependent diabetes mellitus (IDDM). The study found no significant differences in beta-cell secretion between treatment groups, indicating limited efficacy for this intervention.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Clinical Trials

Background:

  • Early-onset insulin-dependent diabetes mellitus (IDDM), also known as type 1 diabetes, is an autoimmune disease.
  • Preserving beta-cell function is crucial for managing IDDM and preventing complications.

Purpose of the Study:

  • To evaluate the effectiveness of nicotinamide in achieving remission in patients with early-onset IDDM.
  • To assess the impact of nicotinamide on pancreatic beta-cell secretion.

Main Methods:

  • A double-blind, randomized clinical trial design was employed.
  • Participants received either nicotinamide or a placebo.
  • Efficacy was measured by remission rates and beta-cell function tests.

Main Results:

  • Nicotinamide treatment did not lead to disease remission in the study cohort.
  • No significant differences in beta-cell secretion were observed between the nicotinamide and placebo groups.
  • The intervention showed no discernible effect on preserving residual beta-cell function.

Conclusions:

  • Nicotinamide is ineffective in inducing remission for early-onset insulin-dependent diabetes mellitus.
  • The trial did not support the use of nicotinamide for improving beta-cell function in this patient population.
  • Further research may be needed to explore alternative therapeutic strategies for IDDM.

Related Concept Videos